Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1807

Showing 26-50 of 1807 citing articles:

Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 83
Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 82
Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1
Yongfeng Tao, David Remillard, Ekaterina V. Vinogradova, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 40, pp. 18688-18699
Open Access | Times Cited: 82
The state of the art of PROTAC technologies for drug discovery
Chao Wang, Cangxin Zheng, Han Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114290-114290
Closed Access | Times Cited: 81
Programming inactive RNA-binding small molecules into bioactive degraders
Yuquan Tong, Yeongju Lee, Xiaohui Liu, et al.
Nature (2023) Vol. 618, Iss. 7963, pp. 169-179
Open Access | Times Cited: 80
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76
Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo
Tianli Luo, Qizhen Zheng, Leihou Shao, et al.
Angewandte Chemie International Edition (2022) Vol. 61, Iss. 39
Closed Access | Times Cited: 75
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 73
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Alexander Hanzl, Ryan Casement, Hana Imrichová, et al.
Nature Chemical Biology (2022) Vol. 19, Iss. 3, pp. 323-333
Open Access | Times Cited: 73
Targeted protein degradation via intramolecular bivalent glues
Oliver Hsia, Matthias Hinterndorfer, Angus D. Cowan, et al.
Nature (2024) Vol. 627, Iss. 8002, pp. 204-211
Open Access | Times Cited: 72
Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway
Natalie C. Sondermann, Sonja Faßbender, Frederick Hartung, et al.
Biochemical Pharmacology (2022) Vol. 208, pp. 115371-115371
Open Access | Times Cited: 70
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 69
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 68
c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer
Xintong Li, Ze Zhang, Fangyan Gao, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 16, pp. 9334-9342
Closed Access | Times Cited: 64
Extracellular targeted protein degradation: an emerging modality for drug discovery
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 61
Aptamer‐LYTACs for Targeted Degradation of Extracellular and Membrane Proteins
Yuqi Wu, Bingqian Lin, Yinzhu Lu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 15
Closed Access | Times Cited: 59
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1210-1229
Open Access | Times Cited: 58
Therapeutic resistance to anti-oestrogen therapy in breast cancer
Marie Will, Jackson Liang, Ciara Metcalfe, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 10, pp. 673-685
Open Access | Times Cited: 58
Glycomimetics for the inhibition and modulation of lectins
Steffen Leusmann, Petra Ménová, Elena Shanina, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 11, pp. 3663-3740
Open Access | Times Cited: 57
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Ingo V. Hartung, Joachim Rudolph, Mary M. Mader, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9297-9312
Open Access | Times Cited: 56
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
Daniel H. O’Donovan, Claudia De Fusco, Lara Kuhnke, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2347-2360
Closed Access | Times Cited: 51
Delivering on the promise of protein degraders
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 51

Scroll to top